Local anesthetic ropivacaine inhibits non-small cell lung cancer progression by modulating the...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide.
• Understanding the molecular mechanisms underlying NSCLC progression is crucial for developing effective therapeutic strategies.
• Ropivacaine, a local anesthetic, has shown potential anti-cancer effects that warrant further investigation.

Purpose of the Study:

• To elucidate the molecular mechanisms by which ropivacaine influences the progression of non-small cell lung cancer (NSCLC).
• To investigate the role of the circ_0001320/miR-518a-5p axis in ropivacaine's anti-cancer effects on NSCLC.

Main Methods:

• NSCLC cells were treated with ropivacaine, and the expression of circ_0001320 and miR-518a-5p was analyzed using RT-qPCR.
• Cell proliferation, apoptosis, migration, and invasion were assessed using CCK-8, flow cytometry, and Transwell assays, respectively.
• Bioinformatic analysis and dual luciferase reporter assays were employed to confirm the interaction between circ_0001320 and miR-518a-5p.

Main Results:

• Ropivacaine suppressed NSCLC cell proliferation, migration, invasion, and angiogenesis, while promoting apoptosis.
• Ropivacaine treatment led to increased expression of circ_0001320 in NSCLC cells.
• Circ_0001320 directly targeted and inhibited miR-518a-5p, and this interaction mediated ropivacaine's inhibitory effects on NSCLC progression.

Conclusions:

• Ropivacaine exerts its anti-cancer effects on NSCLC through the circ_0001320/miR-518a-5p molecular pathway.
• The circ_0001320/miR-518a-5p axis represents a potential therapeutic target for NSCLC treatment.
• These findings provide novel insights into the mechanisms of action of ropivacaine in the context of lung cancer.